News

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis

AUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the publication of novel data on its lead drug candidate, LTI-03, in iScience, a peer-reviewed, open-access journal published by Cell Press.

09/17/2025

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Company to initiate its Phase 2 “RENEW” clinical trial of LTI-03, the Company's lead drug candidate for idiopathic pulmonary fibrosis (IPF). IPF is a serious, progressive lung disease that affects hundreds of thousands of people worldwide.

08/19/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is (RNTX) a buy, sell, or hold?

(RNTX) can sell. Click on Rating Page for detail.

What is 's stock price?

The price of (RNTX) is 1.19 and it was updated on 2025-10-03 13:00:34.

Is (RNTX) overvalued or undervalued?

Currently (RNTX) is in undervalued.

News

From:

To:

News
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that Chief Scientific Officer, Cory Hogaboam, and Chief Executive Officer, Brian Windsor, will each present at the IPF Summit 2025, taking place August 19-21, 2025, in Boston, MA. Dr. Hogaboam will present at 8:00 am on Tuesday in a workshop titled, “Decoding the Disruptions in Natural Biological Processes to Advance Early Intervention in IPF – Unravelling the Molecular Biology of Immune Cells & Inflammation. Thu, Aug. 14, 2025
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders Meeting adjourned to Wednesday, July 23, 2025 at 9:00 a.m. Eastern Time AUSTIN, Texas , June 24, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medications to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it adjourned, without conducting any business, the 2025 annual meeting of stockholders (the "Annual Meeting") on Tuesday, June 24, 2025, due to the fact that a quorum was not achieved and to allow more opportunity for Company stockholders to vote on all proposals described in Rein's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on May 12, 2025. Tue, Jun. 24, 2025
US FDA puts on hold Rein Therapeutics' lung disease drug trial Rein Therapeutics has paused patient enrollment and dosing in a mid-stage trial of its lung disease drug in the U.S. after the Food and Drug Administration placed a clinical hold, the drug developer said on Thursday. Thu, Jun. 12, 2025
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026 AUSTIN, Texas , May 27, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF. "We are pleased to have dosed the first patient in our RENEW Phase 2 trial of LTI-03 following initiation of the trial. Tue, May. 27, 2025
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference Presentations further support the dual mechanism of LTI-03 and the development of Cav1-related peptides for the treatment of idiopathic pulmonary fibrosis (IPF) Company recently initiated RENEW Phase 2 trial evaluating the safety, tolerability and efficacy of LTI-03 in IPF AUSTIN, Texas , May 19, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the Company and its collaborators presented two posters supporting the potential therapeutic effectiveness of LTI-03 in idiopathic pulmonary fibrosis (IPF) at the American Thoracic Society (ATS) 2025 International Conference. "The presentations delivered at ATS today provide further support for the dual mechanism of our lead asset, LTI-03, which has demonstrated sustained alveolar epithelial cell survival as well as inhibition of profibrotic signaling," said Cory Hogaboam, Ph.D. Mon, May. 19, 2025

SEC Filings

SEC Filings
(RNTX) - SCHEDULE 13G/A SEC Filings 09/26/2025
(RNTX) - 8-K - Current report SEC Filings 09/22/2025
(RNTX) - 8-K - Current report SEC Filings 09/09/2025
(RNTX) - EFFECT SEC Filings 09/08/2025
(RNTX) - S-1 SEC Filings 09/03/2025
(RNTX) - 8-K - Current report SEC Filings 08/19/2025
(RNTX) - 10-Q - Quarterly Report SEC Filings 08/14/2025
(RNTX) - 8-K - Current report SEC Filings 07/30/2025
(RNTX) - 424B5 SEC Filings 07/30/2025
(RNTX) - 8-K - Current report SEC Filings 07/23/2025
(RNTX) - 4 SEC Filings 07/23/2025
(RNTX) - DEFA14A SEC Filings 07/11/2025
(RNTX) - 8-K - Current report SEC Filings 07/11/2025
(RNTX) - DEFA14A SEC Filings 06/24/2025
(RNTX) - 8-K - Current report SEC Filings 06/24/2025
(RNTX) - 8-K - Current report SEC Filings 06/12/2025
(RNTX) - EFFECT SEC Filings 05/23/2025
(RNTX) - S-3 SEC Filings 05/16/2025
(RNTX) - SCHEDULE 13G SEC Filings 05/14/2025
(RNTX) - DEFA14A SEC Filings 05/12/2025
(RNTX) - DEF 14A SEC Filings 05/12/2025
(RNTX) - ARS SEC Filings 05/12/2025
(RNTX) - 10-K/A - Current report SEC Filings 04/30/2025
(RNTX) - 8-K - Current report SEC Filings 04/22/2025
(RNTX) - 8-K - Current report SEC Filings 04/17/2025
(RNTX) - 10-K - Current report SEC Filings 04/07/2025
(RNTX) - NT 10-K - Current report SEC Filings 03/31/2025
(RNTX) - 8-K - Current report SEC Filings 01/10/2025
(RNTX) - 4 SEC Filings 12/09/2024
(RNTX) - 4 SEC Filings 12/06/2024
(RNTX) - 4 SEC Filings 12/04/2024
(RNTX) - 8-K - Current report SEC Filings 11/14/2024
(RNTX) - 10-Q - Quarterly Report SEC Filings 11/14/2024
(RNTX) - SCHEDULE 13G/A SEC Filings 11/05/2024
(RNTX) - 4 SEC Filings 08/22/2024
(RNTX) - 8-K - Current report SEC Filings 08/21/2024
(RNTX) - 8-K - Current report SEC Filings 08/14/2024
(RNTX) - 10-Q - Quarterly Report SEC Filings 08/14/2024
(RNTX) - 8-K - Current report SEC Filings 07/26/2024
(RNTX) - 424B5 SEC Filings 07/26/2024
(RNTX) - DEFA14A SEC Filings 07/09/2024
(RNTX) - DEF 14A SEC Filings 07/09/2024
(RNTX) - ARS SEC Filings 07/09/2024
(RNTX) - 4 SEC Filings 06/17/2024
(RNTX) - 4 SEC Filings 06/12/2024
(RNTX) - 4 SEC Filings 06/07/2024
(RNTX) - 8-K - Current report SEC Filings 06/05/2024
(RNTX) - 8-K - Current report SEC Filings 05/16/2024
(RNTX) - 3 SEC Filings 05/16/2024
(RNTX) - 8-K - Current report SEC Filings 05/15/2024
(RNTX) - 10-Q - Quarterly Report SEC Filings 05/15/2024
(RNTX) - 4/A SEC Filings 05/14/2024
(RNTX) - S-8 SEC Filings 05/01/2024
(RNTX) - FWP SEC Filings 05/01/2024
(RNTX) - 8-K - Current report SEC Filings 05/01/2024
(RNTX) - 424B5 SEC Filings 05/01/2024
(RNTX) - 4 SEC Filings 05/01/2024
(RNTX) - 3 SEC Filings 04/30/2024
(RNTX) - 144 SEC Filings 04/29/2024
(RNTX) - 10-K/A - Current report SEC Filings 04/29/2024
(RNTX) - SC 13D/A SEC Filings 04/16/2024
(RNTX) - 8-K - Current report SEC Filings 04/15/2024
(RNTX) - 10-K - Current report SEC Filings 04/15/2024
(RNTX) - 4/A SEC Filings 04/10/2024
(RNTX) - 3 SEC Filings 04/02/2024
(RNTX) - NT 10-K - Current report SEC Filings 04/01/2024
(RNTX) - 8-K - Current report SEC Filings 03/29/2024
(RNTX) - 8-K - Current report SEC Filings 03/15/2024
(RNTX) - 4 SEC Filings 03/06/2024
(RNTX) - SC 13G SEC Filings 03/05/2024
(RNTX) - SC 13D/A SEC Filings 03/05/2024
(RNTX) - 8-K - Current report SEC Filings 03/01/2024
(RNTX) - 4 SEC Filings 03/01/2024
(RNTX) - 8-K - Current report SEC Filings 02/29/2024
(RNTX) - SC 13G/A SEC Filings 02/14/2024
(RNTX) - 8-K - Current report SEC Filings 02/13/2024
(RNTX) - SC 13G/A SEC Filings 02/05/2024
(RNTX) - EFFECT SEC Filings 02/05/2024
(RNTX) - UPLOAD SEC Filings 02/01/2024
(RNTX) - CORRESP SEC Filings 02/01/2024
(RNTX) - DEFA14A SEC Filings 01/31/2024
(RNTX) - S-8 SEC Filings 01/29/2024
(RNTX) - S-3 SEC Filings 01/29/2024
(RNTX) - DEF 14A SEC Filings 01/29/2024
(RNTX) - ARS SEC Filings 01/29/2024
(RNTX) - 8-K - Current report SEC Filings 01/29/2024
(RNTX) - 8-K - Current report SEC Filings 01/25/2024
(RNTX) - PRE 14A SEC Filings 01/19/2024
(RNTX) - 8-K/A - Current report SEC Filings 01/11/2024
(RNTX) - 8-K - Current report SEC Filings 01/10/2024
(RNTX) - 4 SEC Filings 12/18/2023
(RNTX) - 4 SEC Filings 11/21/2023
(RNTX) - D SEC Filings 11/16/2023
(RNTX) - SC 13G SEC Filings 11/13/2023
(RNTX) - SC 13D/A SEC Filings 11/03/2023
(RNTX) - 4 SEC Filings 11/02/2023
(RNTX) - 3 SEC Filings 11/02/2023
(RNTX) - 8-K - Current report SEC Filings 10/31/2023
(RNTX) - 10-Q - Quarterly Report SEC Filings 10/13/2023
(RNTX) - 10-Q - Quarterly Report SEC Filings 08/11/2023
(RNTX) - 10-Q - Quarterly Report SEC Filings 05/08/2023
(RNTX) - 10-K/A - Current report SEC Filings 04/28/2023
(RNTX) - 10-K - Current report SEC Filings 03/20/2023
(RNTX) - 8-K - Current report SEC Filings 02/23/2023
(RNTX) - SC 13G/A SEC Filings 02/14/2023
(RNTX) - 8-K - Current report SEC Filings 11/10/2022
(RNTX) - 10-Q - Quarterly Report SEC Filings 11/01/2022
(RNTX) - 10-Q - Quarterly Report SEC Filings 08/15/2022
(RNTX) - 8-K - Current report SEC Filings 07/08/2022
(RNTX) - 8-K - Current report SEC Filings 06/29/2022
(RNTX) - 424B5 SEC Filings 06/21/2022
(RNTX) - 4 SEC Filings 06/17/2022
(RNTX) - 3 SEC Filings 06/17/2022
(RNTX) - EFFECT SEC Filings 06/16/2022
(RNTX) - 8-K - Current report SEC Filings 06/16/2022
(RNTX) - UPLOAD SEC Filings 06/14/2022
(RNTX) - CORRESP SEC Filings 06/14/2022
(RNTX) - DEL AM SEC Filings 06/13/2022
(RNTX) - S-3 SEC Filings 06/08/2022
(RNTX) - 8-K - Current report SEC Filings 06/08/2022
(RNTX) - 8-K - Current report SEC Filings 06/07/2022
(RNTX) - 10-Q - Quarterly Report SEC Filings 05/05/2022
(RNTX) - DEFA14A SEC Filings 04/29/2022
(RNTX) - DEF 14A SEC Filings 04/29/2022
(RNTX) - 8-K - Current report SEC Filings 04/29/2022
(RNTX) - PRE 14A SEC Filings 04/15/2022
(RNTX) - 424B5 SEC Filings 04/15/2022
(RNTX) - 4/A SEC Filings 03/30/2022
(RNTX) - 10-K - Current report SEC Filings 03/28/2022
(RNTX) - 4 SEC Filings 03/24/2022
(RNTX) - SC 13G/A SEC Filings 02/14/2022
(RNTX) - 8-K - Current report SEC Filings 01/05/2022
(RNTX) - 8-K - Current report SEC Filings 12/07/2021
(RNTX) - 10-Q - Quarterly Report SEC Filings 11/12/2021
(RNTX) - 8-K - Current report SEC Filings 09/17/2021
(RNTX) - 8-K - Current report SEC Filings 09/13/2021
(RNTX) - S-8 SEC Filings 08/11/2021
(RNTX) - 10-Q - Quarterly Report SEC Filings 08/11/2021
(RNTX) - 8-K - Current report SEC Filings 07/01/2021
(RNTX) - 8-K - Current report SEC Filings 06/17/2021
(RNTX) - 4 SEC Filings 06/17/2021
(RNTX) - 10-Q - Quarterly Report SEC Filings 05/11/2021
(RNTX) - DEFA14A SEC Filings 04/28/2021
(RNTX) - DEF 14A SEC Filings 04/28/2021
(RNTX) - PRE 14A SEC Filings 04/16/2021
(RNTX) - 8-K - Current report SEC Filings 03/31/2021
(RNTX) - S-8 SEC Filings 03/24/2021
(RNTX) - 10-K - Current report SEC Filings 03/24/2021
(RNTX) - 8-K - Current report SEC Filings 03/02/2021
(RNTX) - SC 13G/A SEC Filings 02/10/2021
(RNTX) - SC 13G/A SEC Filings 02/09/2021
(RNTX) - EFFECT SEC Filings 02/09/2021
(RNTX) - CORRESP SEC Filings 02/05/2021
(RNTX) - UPLOAD SEC Filings 02/04/2021
(RNTX) - S-3 SEC Filings 01/29/2021
(RNTX) - 8-K - Current report SEC Filings 01/29/2021
(RNTX) - 424B5 SEC Filings 01/29/2021
(RNTX) - SC 13G SEC Filings 01/19/2021
(RNTX) - SC 13D/A SEC Filings 01/08/2021
(RNTX) - 4 SEC Filings 01/08/2021
(RNTX) - 8-K - Current report SEC Filings 01/07/2021
(RNTX) - 424B5 SEC Filings 01/07/2021
(RNTX) - 8-K - Current report SEC Filings 01/06/2021
(RNTX) - 424B5 SEC Filings 12/30/2020
(RNTX) - 8-K - Current report SEC Filings 12/21/2020
(RNTX) - 10-Q - Quarterly Report SEC Filings 11/12/2020
(RNTX) - 8-K - Current report SEC Filings 10/26/2020
(RNTX) - EFFECT SEC Filings 10/15/2020
(RNTX) - 424B3 SEC Filings 10/15/2020
(RNTX) - CORRESP SEC Filings 10/13/2020
(RNTX) - UPLOAD SEC Filings 10/08/2020
(RNTX) - S-1 SEC Filings 10/05/2020
(RNTX) - 424B5 SEC Filings 09/25/2020
(RNTX) - 8-K - Current report SEC Filings 09/22/2020
(RNTX) - 8-K - Current report SEC Filings 09/14/2020
(RNTX) - EFFECT SEC Filings 08/21/2020
(RNTX) - CORRESP SEC Filings 08/19/2020
(RNTX) - UPLOAD SEC Filings 08/18/2020
(RNTX) - S-3 SEC Filings 08/11/2020
(RNTX) - 10-Q - Quarterly Report SEC Filings 08/05/2020
(RNTX) - 4 SEC Filings 06/24/2020
(RNTX) - 8-K - Current report SEC Filings 06/18/2020
(RNTX) - 4 SEC Filings 06/18/2020
(RNTX) - 4 SEC Filings 06/17/2020
(RNTX) - CT ORDER SEC Filings 06/12/2020
(RNTX) - 8-K - Current report SEC Filings 06/11/2020
(RNTX) - SC 13D/A SEC Filings 06/09/2020
(RNTX) - 4 SEC Filings 06/09/2020
(RNTX) - SC 13G SEC Filings 06/08/2020
(RNTX) - 8-K - Current report SEC Filings 06/05/2020
(RNTX) - 424B5 SEC Filings 06/05/2020
(RNTX) - 424B5 SEC Filings 06/03/2020
(RNTX) - 8-K - Current report SEC Filings 06/01/2020
(RNTX) - 10-Q - Quarterly Report SEC Filings 05/11/2020
(RNTX) - DEFA14A SEC Filings 04/28/2020
(RNTX) - DEF 14A SEC Filings 04/28/2020
(RNTX) - 8-K - Current report SEC Filings 04/22/2020
(RNTX) - SC 13D/A SEC Filings 04/16/2020
(RNTX) - PRE 14A SEC Filings 04/16/2020
(RNTX) - SC 13D/A SEC Filings 04/13/2020
(RNTX) - S-8 SEC Filings 03/30/2020
(RNTX) - 10-K - Current report SEC Filings 03/30/2020
(RNTX) - SC 13D/A SEC Filings 03/18/2020
(RNTX) - SC 13G/A SEC Filings 02/14/2020
(RNTX) - SC 13D/A SEC Filings 02/14/2020
(RNTX) - 4 SEC Filings 02/04/2020
(RNTX) - SC 13G/A SEC Filings 02/03/2020
(RNTX) - 8-K - Current report SEC Filings 12/30/2019
(RNTX) - 4 SEC Filings 11/18/2019
(RNTX) - 4 SEC Filings 11/14/2019
(RNTX) - SC 13G/A SEC Filings 11/12/2019
(RNTX) - SC 13G/A SEC Filings 11/08/2019
(RNTX) - 10-Q - Quarterly Report SEC Filings 11/07/2019
(RNTX) - 8-K - Current report SEC Filings 09/30/2019
(RNTX) - 4 SEC Filings 09/16/2019
(RNTX) - 8-K - Current report SEC Filings 09/09/2019
(RNTX) - 4 SEC Filings 09/05/2019
(RNTX) - 4 SEC Filings 09/04/2019
(RNTX) - 4 SEC Filings 09/03/2019
(RNTX) - 4 SEC Filings 08/20/2019
(RNTX) - 4 SEC Filings 08/15/2019
(RNTX) - SC 13D/A SEC Filings 08/13/2019
(RNTX) - 10-Q - Quarterly Report SEC Filings 08/06/2019
(RNTX) - EFFECT SEC Filings 07/16/2019
(RNTX) - POS AM SEC Filings 07/15/2019
(RNTX) - EFFECT SEC Filings 07/15/2019
(RNTX) - 8-K - Current report SEC Filings 07/15/2019
(RNTX) - CORRESP SEC Filings 07/11/2019
(RNTX) - S-3/A SEC Filings 07/01/2019
(RNTX) - 8-K - Current report SEC Filings 06/24/2019
(RNTX) - 4 SEC Filings 06/24/2019
(RNTX) - 3 SEC Filings 06/24/2019
(RNTX) - 4 SEC Filings 06/21/2019
(RNTX) - 8-K - Current report SEC Filings 06/20/2019
(RNTX) - 8-K - Current report SEC Filings 06/05/2019
(RNTX) - UPLOAD SEC Filings 05/23/2019
(RNTX) - EFFECT SEC Filings 05/14/2019
(RNTX) - S-1/A SEC Filings 05/13/2019
(RNTX) - CORRESP SEC Filings 05/10/2019
(RNTX) - 10-Q - Quarterly Report SEC Filings 05/08/2019
(RNTX) - 10-K/A - Current report SEC Filings 05/08/2019
(RNTX) - UPLOAD SEC Filings 05/07/2019
(RNTX) - S-1 SEC Filings 05/01/2019
(RNTX) - DEFA14A SEC Filings 04/30/2019
(RNTX) - DEF 14A SEC Filings 04/30/2019
(RNTX) - SC 13G SEC Filings 04/26/2019
(RNTX) - 4 SEC Filings 04/17/2019
(RNTX) - SC 13D/A SEC Filings 04/11/2019
(RNTX) - SC 13D SEC Filings 04/10/2019
(RNTX) - SC 13G SEC Filings 04/09/2019
(RNTX) - SC 13G SEC Filings 04/08/2019
(RNTX) - SC 13D/A SEC Filings 04/03/2019
(RNTX) - 8-K - Current report SEC Filings 04/03/2019
(RNTX) - 4 SEC Filings 04/03/2019
(RNTX) - 3 SEC Filings 04/03/2019
(RNTX) - 4 SEC Filings 04/02/2019
(RNTX) - 8-K - Current report SEC Filings 04/01/2019
(RNTX) - S-8 SEC Filings 03/29/2019
(RNTX) - 10-K - Current report SEC Filings 03/29/2019
(RNTX) - SC 13D/A SEC Filings 03/18/2019
(RNTX) - 4 SEC Filings 03/15/2019
(RNTX) - 8-K - Current report SEC Filings 03/01/2019
(RNTX) - 4 SEC Filings 02/25/2019
(RNTX) - 3 SEC Filings 02/25/2019
(RNTX) - 8-K - Current report SEC Filings 11/16/2018
(RNTX) - 10-Q - Quarterly Report SEC Filings 11/07/2018
(RNTX) - 4 SEC Filings 11/06/2018
(RNTX) - 3 SEC Filings 11/06/2018
(RNTX) - 8-K - Current report SEC Filings 10/01/2018
(RNTX) - 4 SEC Filings 09/07/2018
(RNTX) - 8-K - Current report SEC Filings 09/06/2018
(RNTX) - SC 13D/A SEC Filings 08/22/2018
(RNTX) - 4 SEC Filings 08/22/2018
(RNTX) - 4 SEC Filings 08/20/2018
(RNTX) - 8-K - Current report SEC Filings 08/17/2018
(RNTX) - 4 SEC Filings 08/16/2018
(RNTX) - UPLOAD SEC Filings 08/15/2018
(RNTX) - 4/A SEC Filings 08/14/2018
(RNTX) - 4 SEC Filings 08/14/2018
(RNTX) - 4 SEC Filings 08/10/2018
(RNTX) - 4 SEC Filings 08/08/2018
(RNTX) - S-3 SEC Filings 08/07/2018
(RNTX) - 10-Q - Quarterly Report SEC Filings 08/07/2018
(RNTX) - 4 SEC Filings 08/06/2018
(RNTX) - 4 SEC Filings 08/02/2018
(RNTX) - 4 SEC Filings 07/31/2018
(RNTX) - 4 SEC Filings 07/27/2018
(RNTX) - 4 SEC Filings 07/25/2018
(RNTX) - 4 SEC Filings 07/18/2018
(RNTX) - SC 13G/A SEC Filings 07/10/2018
(RNTX) - 4 SEC Filings 07/10/2018
(RNTX) - 4 SEC Filings 06/26/2018
(RNTX) - 4 SEC Filings 06/25/2018
(RNTX) - 4 SEC Filings 06/21/2018
(RNTX) - 4 SEC Filings 06/19/2018
(RNTX) - 4 SEC Filings 06/14/2018
(RNTX) - 4 SEC Filings 06/12/2018
(RNTX) - 4 SEC Filings 06/11/2018
(RNTX) - 4 SEC Filings 06/08/2018
(RNTX) - 4 SEC Filings 06/04/2018
(RNTX) - 4 SEC Filings 05/17/2018
(RNTX) - 3 SEC Filings 05/17/2018
(RNTX) - 8-K - Current report SEC Filings 05/16/2018
(RNTX) - S-8 SEC Filings 05/09/2018
(RNTX) - 10-Q - Quarterly Report SEC Filings 05/09/2018
(RNTX) - DEFA14A SEC Filings 04/30/2018
(RNTX) - DEF 14A SEC Filings 04/30/2018
(RNTX) - 4 SEC Filings 04/19/2018
(RNTX) - 8-K - Current report SEC Filings 04/09/2018
(RNTX) - 10-K - Current report SEC Filings 04/02/2018
(RNTX) - 8-K - Current report SEC Filings 03/19/2018
(RNTX) - 4 SEC Filings 03/19/2018
(RNTX) - 3 SEC Filings 03/19/2018
(RNTX) - SC 13G SEC Filings 02/09/2018
(RNTX) - 4 SEC Filings 01/11/2018
(RNTX) - 10-Q - Quarterly Report SEC Filings 11/09/2017
(RNTX) - 4 SEC Filings 09/28/2017
(RNTX) - 10-Q - Quarterly Report SEC Filings 08/10/2017
(RNTX) - 4 SEC Filings 07/27/2017
(RNTX) - SC 13D SEC Filings 07/17/2017
(RNTX) - SC 13D SEC Filings 07/13/2017
(RNTX) - SC 13D/A SEC Filings 07/11/2017
(RNTX) - SC 13D SEC Filings 07/10/2017
(RNTX) - 4 SEC Filings 07/07/2017
(RNTX) - 4 SEC Filings 07/06/2017
(RNTX) - SC 13D SEC Filings 07/05/2017
(RNTX) - S-8 SEC Filings 07/05/2017
(RNTX) - 8-K - Current report SEC Filings 07/05/2017
(RNTX) - 4 SEC Filings 07/05/2017
(RNTX) - 3/A SEC Filings 07/05/2017
(RNTX) - 4 SEC Filings 06/30/2017
(RNTX) - CT ORDER SEC Filings 06/29/2017
(RNTX) - 424B4 SEC Filings 06/29/2017
(RNTX) - EFFECT SEC Filings 06/28/2017
(RNTX) - 3 SEC Filings 06/28/2017
(RNTX) - CORRESP SEC Filings 06/26/2017
(RNTX) - CERTNAS SEC Filings 06/23/2017
(RNTX) - 8-A12B SEC Filings 06/23/2017
(RNTX) - S-1/A SEC Filings 06/19/2017
(RNTX) - CORRESP SEC Filings 06/19/2017
(RNTX) - CORRESP SEC Filings 06/07/2017
(RNTX) - S-1 SEC Filings 06/02/2017
(RNTX) - DRSLTR SEC Filings 05/26/2017
(RNTX) - DRS/A SEC Filings 05/26/2017
(RNTX) - UPLOAD SEC Filings 05/12/2017
(RNTX) - DRS/A SEC Filings 04/17/2017
(RNTX) - D SEC Filings 01/06/2017
(RNTX) - DRS/A SEC Filings 03/28/2016
(RNTX) - DRSLTR SEC Filings 12/29/2015
(RNTX) - DRS/A SEC Filings 12/29/2015
(RNTX) - UPLOAD SEC Filings 10/05/2015
(RNTX) - DRS SEC Filings 09/10/2015
(RNTX) - D SEC Filings 10/29/2014
(RNTX) - D SEC Filings 11/19/2013
(RNTX) - D SEC Filings 06/12/2009
(RNTX) - REGDEX/A SEC Filings 04/23/2008
(RNTX) - REGDEX SEC Filings 12/03/2007

Press Releases

StockPrice Release
Rein therapeutics announces publication of new translational data in iscience on company's novel therapy for idiopathic pulmonary fibrosis 09/17/2025
Rein therapeutics wins u.k. approval to launch phase 2 clinical trial of lti-03 in idiopathic pulmonary fibrosis 08/19/2025
Rein therapeutics to present novel ipf science and clinical development insights at ipf summit 2025 08/14/2025
Rein therapeutics announces adjournment of annual meeting of stockholders 06/24/2025
Rein therapeutics announces first patient dosed in renew phase 2 trial of lti-03 in patients with ipf 05/27/2025
Rein therapeutics presents two posters at the american thoracic society 2025 international conference 05/19/2025
Rein therapeutics reports first quarter 2025 financial results and provides business update 05/15/2025
Rein therapeutics announces initiation of renew phase 2 trial of lti-03 in patients with ipf 05/12/2025
Rein therapeutics and qureight ltd announce planned integration of deep-learning platform for phase 2 trial of lti-03 in patients with ipf 05/01/2025
Rein therapeutics to present at the citizens life sciences conference 2025 04/30/2025
Rein therapeutics announces abstract accepted for presentation at the american thoracic society 2025 international conference 04/28/2025
Rein therapeutics granted two patents covering the novel formulation and administration methods of dry powder lti-03 for the treatment of respiratory diseases 04/23/2025
Rein therapeutics announces a publication in biomedicines on the immunomodulatory and anti-fibrotic properties of a caveolin-1-related peptide in ipf and pasc-f 04/15/2025
Rein therapeutics reports fourth quarter and full year 2024 financial results and provides business update 04/07/2025

More Headlines

News
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) initiated with topline interim data expected in the first half of 2026 Two abstracts accepted to the American Thoracic Society (ATS) 2025 International Conference Cash runway extended following previously announced warrant transactions and private placement AUSTIN, Texas , May 15, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. "Rein has completed a multitude of key accomplishments since the beginning of the year, and we are particularly excited to have initiated the Phase 2 RENEW trial of LTI-03 in patients with IPF," said Brian Windsor, Ph.D. 05/15/2025
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF The RENEW Phase 2 trial will enroll up to 120 IPF patients with topline data expected in the first half of 2026 In the previously reported Phase 1b study, LTI-03 showed a positive trend in seven out of eight biomarkers evaluated in Cohort 2, with five showing dose dependence and four showing statistically significant improvement in the combined Cohort 1 and 2 data set AUSTIN, Texas , May 12, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of idiopathic pulmonary fibrosis (IPF), has been initiated with screening and recruitment of patients underway. "The initiation of the RENEW trial in patients with IPF marks a significant step forward for Rein as we prepare to ultimately identify and share the potential benefits of LTI-03 on patient lung function," said Brian Windsor, Ph.D. 05/12/2025
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF AUSTIN, Texas , May 1, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, today announced a collaboration for the integration of Qureight's deep-learning platform into Rein's planned Phase 2 trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis (IPF). Rein previously announced positive topline results from Cohort 2 (5 mg BID) of the Phase 1b clinical trial of LTI-03 in IPF, in which a positive trend was observed in seven out of eight biomarkers evaluated, with five biomarkers demonstrating dose-dependent effects and four biomarkers achieving statistical significance in the combined Cohort 1 and Cohort 2 data set. 05/01/2025
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 AUSTIN, Texas , April 30, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at The Citizens Life Sciences Conference 2025 on Thursday, May 8, 2025 at 12:00 p.m. 04/30/2025
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference AUSTIN, Texas , April 28, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that an abstract has been accepted at the American Thoracic Society (ATS) 2025 International Conference taking place May 18-21, 2025 in San Francisco, CA. Details of the poster presentation are as follows: Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three Dimensional (3D) Alveolospheres from IPF and Normal Donor Lung Samples Poster #: P1463 Session: B75 Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis Date & Time: Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET About Rein Therapeutics Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. 04/28/2025
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases AUSTIN, Texas , April 23, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the U.S. Patent and Trademark Office (USPTO) granted two new patents related to Rein's lead product candidate, LTI-03, a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling, which is administered through dry powder inhalation. U.S. Patent No. 04/23/2025
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F Manuscript highlights the effects of caveolin scaffolding domain peptide LTI-2355 on myeloid cell activity in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) AUSTIN, Texas , April 15, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) in the peer-reviewed journal, Biomedicines. The manuscript, titled "Caveolin Scaffolding Domain (CSD) Peptide LTI-2355 Modulates the Phagocytic and Synthetic Activity of Lung-Derived Myeloid Cells in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F)," describes the effects of caveolin scaffolding domain (CSD) peptide LTI-2355 on the immune and synthetic properties of human lung-derived macrophages and other myeloid cells isolated from lung explant tissue of donor lungs, as well as IPF and PASC-F lung explant tissue. 04/15/2025
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) in the first half of 2025 Positive topline results from Cohort 2 (5 mg BID) of the Phase 1b clinical trial of LTI-03 in IPF patients demonstrated dose dependent effects in five biomarkers evaluated, with four biomarkers achieving statistical significance in the combined Cohort 1 and Cohort 2 data set AUSTIN, Texas , April 7, 2025 /PRNewswire/ -- Rein Therapeutics, Inc. (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. "We've made significant clinical progress during 2024, culminating in promising safety and positive topline data from our Phase 1b trial of LTI-03 in IPF patients, which demonstrated early signs of therapeutic effect. 04/07/2025

Unlock

RNTX Ratings Summary

RNTX Quant Ranking